Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
30 Sep, 26
The updated guideline for stage I-III HER2-positive, HER2-negative breast cancer emphasizes endocrine therapy as the treatment foundation, with chemotherapy & targeted therapies tailored by clinical features, genomic risk & treatment tolerance.
30 Sep, 26
The guidelines for advanced gastroesophageal cancer emphasize early biomarker testing & personalized use of immunotherapy & targeted therapies, with treatment selection guided by HER2, PD-L1, CLDN18.2, & MSI/MMR status to optimize patient outcomes.
29 Sep, 26
BMC Infect. Dis.
- Higher albumin-to-glucose ratio (AGR) independently reduced 30-day mortality risk by 18% (adjusted HR 0.82; P<0.001)
- AGR showed good prognostic discrimination with an optimal cutoff of ≥5.0 (AUC 0.713); platelet count mediated only 9.24% of the AGR-mortality association
- Patients with low AGR and low platelet count had a 4.04-fold higher crude mortality risk (HR 4.04; P<0.001)
28 Sep, 26Obesity Med.
- Of the 833 adults in India with HTN &/or DM attending an NCD clinic, 70.7% had clinical obesity, highest in HTN alone (88%), with significantly elevated BMI & Conicity Index
- Clinical obesity was independently linked with age 60-69 yrs, extended family, HTN duration >10 yrs, tobacco use, & coexistence of HTN+DM
- Sensitivity analysis showed a lower obesity burden (50%) but retained significant predictor links.
25 Sep, 26J. Cos. Dermatol.
- In this randomized trial, 156 subjects received a novel HA-based injection or established HA filler for moderate-to-severe horizontal neck wrinkles
- At wk 4, ≥1-point improvement on the Allergan Transverse Neck Lines Scale was achieved in 83.3% vs 71.8% of patients (difference: 11.54%)
- The novel HA filler demonstrated non-inferior efficacy, with comparable safety & no serious adverse events reported.
24 Sep, 26Cardiovasc Diabetol.
- Among 6023 adults with CKM stages 0-3, 399 developed CMM in 9 yrs
- Each 1-SD rise in TyG-FI, CTI-FI, CHG-FI, & SHR-FI raised CMM risk by 27-31% (HR 1.27-1.31), while higher eGDR/FI cut risk by 39% (HR 0.61)
- Concurrent insulin resistance & frailty conferred greatest risk, with CHG+FI (HR 6.47) & CTI+FI (HR 6.27)
- An integrated insulin resistance-frailty assessment may improve early CMM stratification (AUC: 0.742)
29 Sep, 26
Featured
30 Sep, 26
28 Sep, 26
28 Sep, 26
